9 October 2024

To: Recipients of CLSI MM26-Ed1

From: Jennifer K. Adams, MLS(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of corrections made to CLSI MM26, *Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation,* 1st ed. The corrections are described below and shown as highlighted and/or stricken text in the table excerpt.

Table 2. Hematologic Neoplasms: Correlation of Diagnostic Category With Molecular Findings:

The first subheading is listed incorrectly as "Myeloid Neoplasms." The subheading has been corrected to read "Chronic Myeloid Neoplasms."

In the sixth row under the "AML and Related Precursor Neoplasms" subheading, "*GATA2*" is listed incorrectly as "*GAT2.*" The text has been corrected to read "*GATA2*."

The fourth subheading is listed incorrectly as "Mature B-cell Neoplasms." This heading is technically incorrect and has been removed. For added clarity, the third subheading, "Lymphoid Neoplasms," has been revised to read "Lymphoid, Histiocytic, and Related Neoplasms."

Table 2. Hematologic Neoplasms: Correlation of Diagnostic Category With Molecular Findings

Category of Hematologic Neoplasms[a]	Common and/or Characteristic Genetic Abnormalities
Chronic Myeloid Neoplasms	
MPN	*BCR::ABL1*, *CALR*, *CSF3R*, *JAK2*, *MPL* (m)
Myelodysplastic syndromes	*ASXL1*, *DNMT3A*, *EZH2*, *SF3B1*, *SRSF2*, *STAG2*, *TET2*, *TP53*, *U2AF1*, *ZRSR2* (m)
Myelodysplastic syndromes and/or MPN	*ASXL1*, *CALR*, *CBL*, *ETNK1*, *JAK2*, *KRAS*, *MPL*, *NF1*, *NRAS*, *PTPN11*, *SETBP1*, *SF3B1*, *SRSF2*, *TET2* (m)
Mastocytosis	*KIT* (m)
AML and Related Precursor Neoplasms	
AML with defining genetic abnormalities	*BCR::ABL1*, *CBF::MYH11*, *CEBPA*, *DEK::NUP214*, *KMT2A* (re), *MECOM* (re), *NUP98* (re), *NPM1* (m), *PML::RARA*, *RBM1::MKL1*, *RUNX1::RUNX1T1*
AML, myelodysplasia related	*ASXL1*, *BCOR*, *DNMT3A*, *ETV6*, *EZH2*, *IDH1*, *IDH2*, *RUNX1*, *SETBP*, *SF3B1*, *SRSF2*, *STAG2*, *TET2*, *TP53*, *U2AF1* (m)
AML, defined by differentiation	*ASXL1*, *CEBPA*, *DNMT3A*, *FLT3*, *IDH1*, *IDH2*, *NPM1*, *NRAS*, *PTPN11*, *RUNX1*, *SRSF2*, *STAG2*, *TET2*, *TP53*, *WT1* (m)
Secondary myeloid neoplasms	*TP53*, *PPM1D* (m)
Myeloid proliferations associated with Down Syndrome (newborns)	*GATA1* (m)
Myeloid neoplasms with germline predisposition	• *ANKRD26*, *BLM*, *CEBPA*, *DDX41*, *ETV6*, *GATA2*, *RUNX1*, *SAMD9*, *SAMD9L*, *TP53* (m) • RASopathies (eg, *KRAS*, *CBL*) and/or overgrowth syndromes and telomeropathies, DNA repair genes, and/or ribosomal genes associated with bone marrow failure syndromes
Lymphoid, Histiocytic, and Related Neoplasms	
B-lymphoblastic leukemia and/or lymphoma	*BCR::ABL1*, *BCR-ABL1*-like signatures, *ETV6::RUNX1*, *iAMP21*, *IGH::IL3*, *IKZF1* (m, del, re), *KMT2A* (re), *TCF3::HLF*, *TCF3::PBX1*
T-lymphoblastic leukemia and/or lymphoma	*HOXA*, *LYL1*, *TAL1*, *TLX1*, *TLX3* (re) with T-cell receptor genes, *NOTCH1* (m)
~~**Mature B-cell Neoplasms**~~	
Chronic lymphocytic leukemia and/or small lymphocytic lymphoma	*ATM* (m, del), *IGH* (re), *NOTCH1* (m), *SF3B1* (m), *TP53* (m, del), *XPO1* (m)
Hairy cell leukemia and variants	*BRAF* (m), *MAP2K1* (m)
Other B-cell lymphomas	*BCL2*, *BCL6* (re) with *IGH*, *IGK*, or *IGL*, *BRAF*, *CREBBP*, *KMT2D*, *MYC*, *MYD88*, *TP53* (m)

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).